Synergetic hemostatic potential of fibrinogen γ‐chain peptide‐coated, adenosine 5′‐diphosphate‐encapsulated liposomes combined with whole blood transfusion: A preclinical study

Background Whole blood (WB) transfusions are being reevaluated because of their high hemostatic capacity and reduced volume. Fibrinogen γ‐chain peptide‐coated, adenosine 5′‐diphosphate (ADP)‐encapsulated liposomes are potent hemostatic adjuvants promoting platelet thrombi formation. This study aimed to elucidate the potential interactions between simultaneous WB transfusion and the administration of fibrinogen γ‐chain peptide‐coated ADP‐encapsulated liposomes. Study Design and Methods We used a rabbit model of postcardiopulmonary bypass (CPB) coagulopathy. One hour after CPB, the rabbits were transfused with WB (WB group, n = 7) or H12‐ADP‐liposomes along with WB transfusion (WB + H12‐ADP‐liposome group, n = 7). Blood cell counts, coagulation activity, platelet function, and bleeding time were evaluated. Results Hemoglobin concentration, platelet count, activated clotting time, and ADP and collagen test results were comparable between the WB + H12‐ADP‐liposome and WB groups after transfusion. However, bleeding time was remarkably reduced in the WB + H12‐ADP‐liposome group (378 ± 150 s) compared with that in the WB group (551 ± 255 s, p < .01), suggesting that H12‐ADP‐liposomes further enhanced the hemostatic effect of WB transfusion in post‐CPB coagulopathy. Discussion Administration of H12‐ADP‐liposomes along with WB transfusion had a synergistic effect on hemostatic performance, providing a greater therapeutic advantage than WB transfusion alone.